Generics - Financial, Actavis

Filter

Current filters:

FinancialActavis

Popular Filters

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

20-02-2014

Acquisitive Ireland-headquartered generics major Actavis says that net revenue leapt 59% to $2.779 billion…

ActavisFinancialGenerics

Actavis refocuses global business structure; reiterates 2014 outlook

Actavis refocuses global business structure; reiterates 2014 outlook

01-02-2014

US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of…

ActavisBoardroomFinancialGenerics

Actavis cuts 350 sales staff after acquisition of Warner Chilcott

Actavis cuts 350 sales staff after acquisition of Warner Chilcott

22-11-2013

US generics major Actavis (NYSE: ACT) says it has completed the restructuring of its US Specialty Brands…

ActavisFinancialGenericsManagementNorth AmericaUSAWarner Chilcott

Bumper 3rd-qtr for Actavis, with 57% net revenue leap

Bumper 3rd-qtr for Actavis, with 57% net revenue leap

29-10-2013

US generics major Actavis has reported a net revenue increase of 57% to $2.01 billion for the third quarter…

ActavisFinancialGenerics

Highs and lows as Actavis 2nd qtr results meet expectations

25-07-2013

US generics drug major Actavis (NYSE: ACT) reported its net revenue increased 46.8% to $1.99 billion…

ActavisFinancialGenericsNorth AmericaWarner Chilcott

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Actavis and Warner Chilcott leap on merger talks; possible bid for Adcock Ingram

13-05-2013

US generics major Actavis NYSE: ACT) confirmed on Friday (May 10) that it has entered into early stage…

ActavisAdcock IngramFinancialGenericsMergers & AcquisitionsPharmaceuticalWarner Chilcott

Actavis and Valeant report first quarter 2013 results

02-05-2013

US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Lower 4th-qtr 2012 profits at Actavis but beat expectations

19-02-2013

US generics major Actavis (NYSE: ACT, the new name for the Watson business) reported net revenue increased…

ActavisFinancialGenericsWatson Pharmaceuticals

Watson Pharma now trading as Actavis; Dr Reddy's debuts generic Clarinex Reditabs in USA

28-01-2013

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) announced last week that the company has adopted…

ActavisClarinex ReditabsDr Reddy's LaboratoriesFinancialGenericsManagementMarkets & MarketingWatson Pharmaceuticals

Watson 3rd-qtr EPS jumps 24%, as revenues rise 19%

01-11-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has reported that net income for the third quarter…

ActavisFinancialGenericsWatson Pharmaceuticals

Fitch puts Watson on rating watch Negative on planned acquisition of Actavis

26-04-2012

US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has seen its rating downgraded by Fitch Ratings,…

ActavisFinancialGenericsMergers & AcquisitionsNorth AmericaWatson Pharmaceuticals

Back to top